貝達藥業(300558.SZ):擬斥不超8000萬美元認購Xcovery新發行F輪優先股 持股比例升至69.53%
格隆匯10月8日丨貝達藥業(300558.SZ)公佈,2021年10月8日,公司第三屆董事會第二十四次會議審議通過《關於認購Xcovery新發行F輪優先股的議案》,公司擬通過全資子公司貝達投資(香港)有限公司(簡稱“貝達香港”)以不超過5.8129美元每股的價格認購控股子公司Xcovery Holdings, Inc.(簡稱“Xcovery”)新發行F輪優先股,按持股比例認購金額及超額認購金額合計不超過8000萬美元。
Xcovery是2009年9月22日在美國特拉華州(Delaware)成立的一家專注利用小分子激酶抑制劑開發新一代癌症治療藥物的研發公司,是貝達香港的控股子公司,擁有全資子公司Equinox Science, LLC。Xcovery全面負責恩沙替尼(Ensartinib,X-396)項目(新一代ALK抑制劑,用於治療ALK突變的非小細胞肺癌患者)和Vorolanib (X-82)項目在中國境外的開發和運作。目前,恩沙替尼項目正在開展全球多中心III期臨牀試驗。
該次認購完成後,公司將持有Xcovery約4779.46萬股,持股比例增加至69.53%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.